SAU:4016
Middle East Pharmaceutical Industries Company · SAU · Healthcare · SAR · FY for 2025
Figures on this page computed 2026-11-06 18:07 UTC
Last close
n/aSAR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
23.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
- Computed from the filing for 2025
22.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
21.1%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
17.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.15Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
What it pays out is the furthest below its sector's middle: 0.35 against 0.54 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.39x
Its own average over 7 years, 330.9M.
- Profit1.37x
Its own average over 7 years, 70.8M.
- Free cash flow1.95x
Its own average over 7 years, 40.3M.
- Debt1.02x
Its own average over 7 years, 62.3M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 1.95 times.
The filed years, as a table
7Each line is 100 at 2019-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2019-12-31 | 100.0 | 100.0 | 100.0 |
| 2020-12-31 | 130.0 | 134.7 | 100.0 |
| 2021-12-31 | 123.8 | 122.6 | 100.0 |
| 2022-12-31 | 130.4 | 110.0 | 100.0 |
| 2023-12-31 | 145.8 | 121.8 | 100.0 |
| 2024-12-31 | 169.8 | 147.7 | 128.4 |
| 2025-12-31 | 198.4 | 179.5 | 100.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SAR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SAR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SAR
Figures behind the shape
Growth
8.8%faster is higher, placed against 4,940 companies as of 2026-11-05
Five-year revenue growth rate8.8%
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
Five-year EPS growth rate5.9%
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
One-year change in net income21.5%
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
Returns on capital
22.7%higher is higher, placed against 5,079 companies as of 2026-11-05
Return on invested capital22.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity23.3%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets16.2%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
62.3%wider is higher, placed against 3,410 companies as of 2026-11-05
Gross margin62.3%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin23.5%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin21.1%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin17.0%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
23.4xcheaper is higher, placed against 4,359 companies as of 2026-11-05
Price to earnings23.4x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
- Computed from the filing for 2025
Price to book5.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA17.9x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio4.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.15safer is higher, placed against 3,226 companies as of 2026-11-05
Debt to equity0.15
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.13
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage23.2x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score9.89
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
48.4%more, and better covered, is higher, placed against 1,089 companies as of 2026-11-05
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
Payout ratio48.4%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio1.7x
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- SAR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.